Karen Liu

Karen Liu is a Partner at 3E Bioventures, a venture capital fund focused on life sciences, investing in biotechnology and TechBio innovations. Liu serves as a Board Member for multiple companies, including Biosion, Dermaliq Therapeutics, Neural Galaxy, SHANTON PHARMA, Rapafusyn Pharmaceuticals, Purinomia Biotech, Avirmax, Ansun Biopharma, and Quadriga BioSciences, contributing expertise in drug discovery and development across various therapeutic areas. Educational qualifications include a Ph.D. in Immunology from Harvard University, a Master of Medical Sciences from Harvard Medical School, a Bachelor of Science in Biochemistry from Cornell University, and an Executive MBA from Cheung Kong Graduate School of Business.